Abstract
BackgroundIn ORAL Surveillance, a post-approval safety study conducted in RA patients aged ≥50 years with ≥1 cardiovascular (CV) risk factor, non-inferiority was not shown for MACE and malignancy (excluding nonmelanoma...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
